{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for edaravone in Reference Text / Citation (approximate match)
Status:
US Approved Rx
(2017)
Source:
NDA209176
(2017)
Source URL:
First approved in 2017
Source:
NDA209176
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Edaravone is a free radical scavenger developed for the treatment of amyotrophic lateral sclerosis.
